Document is current
Any future updates will be listed below
-
Authors
Bhave, Manali
Jhaveri, Komal L.
Kaufman, Peter A.
Aftimos, Philippe
Lombard, Janine
Giridhar, Karthik V.
Im, Seock-Ah
Ma, Cynthia X.
Lee, Kuo-Ting
Kim, Sung-Bae
Sohn, Joohyuk
Li, Yujia
Yuen, Eunice
Estrem, Shawn T.
Nguyen, Bastien
Makena, Monish Ram
Ismail-Khan, Roohi
Beeram, Muralidhar
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04188548 at ClinicalTrials.govDocuments that mention this clinical trial
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.
https://doi.org/10.1200/jco.2024.42.16_suppl.1027
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
https://doi.org/10.1200/jco.23.02733
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study
https://doi.org/10.1186/s13058-025-02168-6
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.
https://doi.org/10.1200/jco.2024.42.16_suppl.5589
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 9 June 2025
Accepted: 30 October 2025
First Online: 21 December 2025
Declarations
:
: The study was approved by the ethical/institutional review boards and conducted according to the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice Guideline, and applicable regulatory requirements. All patients provided written informed consent.
: Manali Bhave: Consulting or Advisory Role: Daiichi Sankyo/AstraZeneca, Merck, Lilly, Pfizer, Gilead SciencesKomal L. Jhaveri: Consulting or Advisory Role: Novartis, Pfizer, AstraZeneca, Jounce Therapeutics, Synthon, Intellisphere, Bristol Myers Squibb, Genentech, AbbVie, Lilly, BluePrint Medicines, Seagen, Daiichi Sankyo, Biotheranostics, Sun Pharma Advanced Research Company, Taiho Oncology, Sanofi, Gilead Sciences, Eisai, Bicycle Therapeutics, Scorpion TherapeuticsResearch Funding: Novartis (Inst), Genentech (Inst), Debiopharm Group (Inst), ADC Therapeutics (Inst), Pfizer (Inst), Novita Pharmaceuticals (Inst), Clovis Oncology (Inst), Lilly (Inst), Zymeworks (Inst), Immunomedics (Inst), Puma Biotechnology (Inst), VelosBio/Merck (Inst), AstraZeneca (Inst), Context Therapeutics (Inst), Scorpion Therapeutics (Inst), Eisai (Inst), Rayzebio (Inst)Blueprint Medicines (Inst)Travel, Accommodations, Expenses: Taiho Pharmaceutical, Jounce Therapeutics, Pfizer, AstraZeneca, Intellisphere, Lilly, Gilead Sciences, Genentech/RochePeter A. Kaufman:Stock and Other Ownership Interests: Amgen, Johnson & Johnson/JanssenHonoraria: Lilly, Eisai, AstraZenecaConsulting or Advisory Role: Polyphor, Roche/Genentech, Lilly, Eisai, Macrogenics, Pfizer, Merck, AstraZeneca, Sanofi, Seagen, Sermonix PharmaceuticalsSpeakers’ Bureau: LillyResearch Funding: Eisai (Inst), Polyphor (Inst), Lilly (Inst), Novartis (Inst), Pfizer (Inst), Sanofi (Inst), Zymeworks (Inst), Sermonix Pharmaceuticals (Inst)Expert Testimony: SeagenTravel, Accommodations, Expenses: Lilly, Polyphor, SeagenPhilippe Aftimos: Honoraria: Synthon, Roche, Gilead SciencesConsulting or Advisory Role: Macrogenics, Boehringer Ingelheim, Novartis, Amcure, Roche, Amgen, Servier, G1 Therapeutics, Radius Health, Deloitte, Menarini, Gilead Sciences, Incyte, Lilly, OlemaResearch Funding: Roche (Inst)Travel, Accommodations, Expenses: Amgen, MSD Oncology, Roche Belgium, Pfizer, Daiichi Sankyo/AstraZeneca, Gilead SciencesJanine Lombard: Honoraria - AstraZeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Novartis Consulting or Advisory Role – AstraZeneca Travel, Accommodations, Expenses – LillyKarthik V. Giridhar: Research funding: Guardant Health; Advisory board: AstraZeneca, Eli Lilly and Company, Novartis, Neogenomics, TerSera Therapeutics, Puma Biotechnology. Attending meeting and/or travel: Eli Lilly and Company, Grail Inc.Seock-Ah Im: Consulting or Advisory Role: AstraZeneca, Novartis, Roche/Genentech, Eisai, Pfizer, Amgen, Hanmi, Lilly, MSD, Daiichi Sankyo Research Funding: AstraZeneca (Inst), Pfizer (Inst), Roche/Genentech (Inst), Daewoong Pharmaceutical (Inst), Eisai (Inst), Boryung Pharmaceuticals (Inst) Other Relationship: RocheCynthia X. Ma: Consulting or Advisory Role: Novartis, AstraZeneca, Biovica Inc, Olaris, Gilead Sciences, Pfizer, Lilly, Tempus, Genzyme, Tersera, Stemline Therapeutics, Daiichi Sankyo/AstraZeneca, Regor Therapeutics Group, Danatlas, Merck Research Funding: Pfizer (Inst), Puma Biotechnology (Inst) Kuo-Ting Lee: no conflicts to disclose.Sung-Bae Kim: Stock and Other Ownership Interests: Genopeaks Honoraria: Daehwa Pharmaceutical, LegoChem Biosciences, Kalbe Farma Consulting or Advisory Role: Lilly (Inst), AstraZeneca, Daehwa Pharmaceutical, ISU Abxis, BeiGene, Daiichi Sankyo/AstraZeneca, OBI Pharma, Ensol Biosciences Research Funding: Genzyme (Inst)Yujia Li: Employment: Lilly, Memorial Sloan-Kettering Cancer Center Stock and Other Ownership Interests: Lilly, Pfizer, Illumina Travel, Accommodations, Expenses: LillyEunice Yuen: Employment: Lilly Stock and Other Ownership Interests: LillyShawn T. Estrem: Employment: Lilly Stock and Other Ownership Interests: LillyBastien Nguyen: Employment: Loxo/LillyMonish Ram Makena: Employment: Loxo/LillyRoohi Ismail-Khan: Employment: Eli Lilly/Loxo Oncology Stock and Other Ownership Interests: LillyJoohyuk Sohn: Stock and Other Ownership Interests: Daiichi Sankyo Research Funding: MSD (Inst), Roche (Inst), Novartis (Inst), Lilly (Inst), Pfizer (Inst), Daiichi Sankyo (Inst), AstraZeneca (Inst), GlaxoSmithKline (Inst), Sanofi (Inst), Boehringer Ingelheim (Inst), Seagan (Inst), Qurient (Inst), Dragonfly Therapeutics (Inst), Eikon (Inst), Gilead Sciences (Inst), Celcuity (Inst), Bristol Myers Squibb (Inst), HLB Life Science (Inst), Sermonix Pharmaceuticals (Inst), Olema Oncology (Inst), Hanmi Pharm (Inst), Ildong Pharmaceutical (Inst), Samyang Holdings (Inst)Muralidhar Beeram: Honoraria: Genentech (Inst), Johnson & Johnson (Inst) Consulting or Advisory Role: Novartis, Bayer, Merck, Seagen Speakers’ Bureau: Genentech (Inst), Merck (Inst), Bristol Myers Squibb (Inst) Research Funding: Lilly (Inst), Zymeworks (Inst), Mersana (Inst), Phoenix Molecular Designs (Inst), Merrimack (Inst), Agios (Inst), Puma Biotechnology (Inst), Merck (Inst), AstraZeneca (Inst) Travel, Accommodations, Expenses: Genentech, Merck.
